Arpeggio Biosciences has filed a notice of an exempt offering of securities to raise $35,318,765.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Arpeggio Biosciences, Inc. is raising up to $35,318,765.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Arpeggio Biosciences, Inc.
Arpeggio is developing the world’s fastest platform for transcriptomic sequencing to learn how chemistry maps to network biology. 99.5% of adults over fifty will have a chronic disease by 2040. We’re working on developing a pipeline of potential drugs to tackle drug resistance in cancer, chronic kidney disease, and neurodegeneration. Arpeggio is a team of computer scientists, biologists, and entrepreneurs using functional genomics to find new therapeutic targets for hard to treat diseases like cancer. We believe that building tomorrows medicines will require an integrated perspective that combines ideas and methods from disparate scientific fields. Our team and the work we do directly reflects this multidisciplinary approach.
To learn more about Arpeggio Biosciences, Inc., visit https://www.arpeggiobio.com/
Arpeggio Biosciences, Inc. Linkedin Page: https://www.linkedin.com/company/arpeggio-biosciences/
Contact:
Joseph Azofeifa, President and Chief Executive Officer
402-525-6851
https://www.linkedin.com/in/joeyazofeifa
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
